Cytek CTO exercises RSUs, withholds shares for tax

Cytek Biosciences, Inc. director and Chief Technology Officer Yan Ming reported equity compensation activity involving restricted stock units (RSUs) and common stock.

Rhea-AI Filing Summary

Cytek Biosciences, Inc. director and Chief Technology Officer Yan Ming reported equity compensation activity involving restricted stock units (RSUs) and common stock. On February 18, 2026, 1,332 RSUs were converted into 1,332 shares of common stock at a stated price of $0.0000 per share.

On the same date, 395 shares of common stock at $4.20 per share were withheld and surrendered to Cytek to cover tax obligations arising from the RSU vesting, described as a tax-withholding disposition rather than an open-market sale. Following these transactions, Yan Ming directly held 6,074,264 common shares.

Insider Trade Summary

1,332 shares exercised/converted

Exercise 3 txns

Insider Yan Ming

Role CHIEF TECHNOLOGY OFFICER

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	1,332	$0.00	$0.00
Exercise	Common Stock	1,332	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	395	$4.20	$2K

Holdings After Transaction: Restricted Stock Units — 0 contracts (Direct); Common Stock — 6,074,264 shares (Direct)

Footnotes (3)

1. F1. Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.
2. F2. Represents the number of shares withheld by and surrendered to the Issuer on February 18, 2026, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award.
3. F3. The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Yan Ming report at Cytek Biosciences (CTKB)?

Yan Ming reported RSU vesting and related share movements at Cytek Biosciences. 1,332 restricted stock units converted into 1,332 common shares, and 395 shares were withheld and surrendered to the company to satisfy tax withholding obligations connected to the RSU vesting event.

Did Yan Ming buy or sell Cytek Biosciences (CTKB) stock on the open market?

The Form 4 shows no open-market purchase or sale by Yan Ming. Shares were acquired through RSU conversion and 395 shares were disposed of solely to satisfy tax withholding obligations, with the shares withheld and surrendered directly to Cytek Biosciences rather than sold in the market.

How many Cytek Biosciences shares did Yan Ming hold after the reported transactions?

After the reported RSU conversion and tax-withholding disposition, Yan Ming directly held 6,074,264 shares of Cytek Biosciences common stock. This figure reflects the Form 4’s stated ownership following the 1,332-share RSU conversion and the surrender of 395 shares for tax withholding purposes.

What do the restricted stock units (RSUs) in Yan Ming’s Cytek Biosciences filing represent?

Each RSU represents a contingent right to receive one share of Cytek Biosciences common stock. According to the filing, the RSU award vests quarterly over four years on specified dates, with portions of the total underlying shares vesting at each quarterly vesting date.

How is Yan Ming’s RSU award at Cytek Biosciences (CTKB) scheduled to vest?

The RSU award vests quarterly over four years. 4/48ths of the total underlying shares vested on May 18, 2022, and 3/48ths of the total underlying shares vest on each subsequent quarter: August 18, November 18, February 18, and May 18 during the vesting period.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/20/2026 - 05:47 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Yan Ming

(Last) (First) (Middle)

C/O CYTEK BIOSCIENCES, INC.

47215 LAKEVIEW BOULEVARD

(Street)

FREMONT CA 94538

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cytek Biosciences, Inc. [ CTKB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF TECHNOLOGY OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/18/2026		M		1,332	A	(1)	6,074,659	D
Common Stock	02/18/2026		F		395(2)	D	$4.2	6,074,264	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	02/18/2026		M			1,332	(3)	(3)	Common Stock	1,332	$0	0	D

Explanation of Responses:

1. Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.

2. Represents the number of shares withheld by and surrendered to the Issuer on February 18, 2026, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award.

3. The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18.

	/s/ Valerie Barnett, Attorney-in-Fact	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.